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among patients. ConClusions: Based on our research among patients we con-
clude that generic substitution is most likely effective drug policy tool, but since 
there are also many negative experiences (own or shared) with generic drugs, GS is 
still considered as alternative treatment.
PHP3
THe SimulTaneouS effecTS of PHarmaceuTical PolicieS from PayerS’ 
and PaTienTS’ PerSPecTiveS. iTaly aS a caSe STudy
Armeni P.1, Otto M.H.2, Jommi C.1
1Cergas, Bocconi University, Milano, Italy, 2CERGAS Bocconi University, Milano, Italy
objeCtives: The research analyses (i) the individual and interactive effects of 
three pharmaceutical policies (cost-sharing, prescription quotas, therapeutic ref-
erence pricing) on drugs public and private expenditure and volumes, using Italian 
regional policies as a case-study; (ii) the extent to which the long-run effect of poli-
cies on expenditure is mediated by prescribers’/patients’ behaviours. Methods: 
An enriched difference-in-differences model is used. Firstly, policies impact on 
public and private expenditure and volume is separately estimated. Then, the 
hypothesis that the effects of policies on public expenditure are mediated by behav-
iours (transmission mechanism) is tested. As robustness check, a possible reverse 
causality and feedback mechanisms is tested, by switching the mediator and the 
independent variable. Results: The analysis shows (i) that combined policies do 
not necessarily produce a higher impact than policies alone; (ii) a larger impact 
of policies in the short-run, whereas in the long-run the trend is often reversed, 
but not enough to compensate the final impact, which is usually in the expected 
direction; (iii) as for cost-sharing, that its negative impact on public expenditure is 
mainly due to a decrease in volumes than to a shift from public to private expendi-
ture. ConClusions: Despite its limitation, this study has shined a light on the 
impact of policies which are implemented in different time and places, thus cover-
ing an information gap and supporting policy-makers. Some empirical findings 
show also that pharmaceutical policies may have an unintended impact on health: 
e.g. the volumes decrease due to cost-sharing may imply patients under-treatment.
PHP4
PaTienT, inSuree and Public ParTiciPaTion in HealTH TecHnology 
aSSeSSmenT: an inTernaTional comPariSon
Mühlbacher A.C., Juhnke C.
Hochschule Neubrandenburg, Neubrandenburg, Germany
objeCtives: There is a general consensus on the need for a stronger patient-cen-
teredness, even in HTA processes. In international comparison different ways of 
public participation (citizens, insured and patients) in the decision-making process 
are discussed and tested. The need was recognized, but not yet fully reflected in 
practice. This study describes how preferences can be taken into account in dif-
ferent decision situations and shows how methods of preference measurement/
citizens’ councils are used in an international context to support decision-making 
and understand the importance of various decision-criteria that influence these 
decisions. Methods: A systematic literature review in PubMed/Medline revealed 
95 articles and showed that methods of patients, citizens and policyholder par-
ticipation are manifold. In order to structure the international approaches further, 
international HTA-organizations worldwide were questioned via e-mail in the end of 
2013 on patients and public participation in their countries. Results: 17 out of 126 
contacted organizations answered to these questions. In general, the participation 
efforts extend from qualitative survey of patients’ needs up to the science-based 
documentaries of quantitative patient preferences. The review and the survey of 
the HTA-agencies show that internationally three mechanisms are used to involve 
the public in decision-making bodies: membership of at least one patient representative 
(e.g., Australia, France, Germany), presentation of oral/written comments from patients 
(e.g., Australia, The Netherlands, Great Britain) and the possibility to check the HTA-
reports and the corresponding draft recommendations before publication (e.g., France, 
Germany, Great Britain, New Zealand, USA). ConClusions: The role of the 
patients or citizens seems to be limited to an informal or ad-hoc basis and is mostly 
restricted to consulting activities. In order to achieve a patient-centered health 
technology assessment two ways to sharing information are relevant: the public 
needs information on medical and health policy/economic issues and decision-
maker need information on the patient perspective.
HealTH care uSe & Policy STudieS – diagnosis related group
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objeCtives: Diagnosis Related Groups (DRG) like financing method was introduced 
in Hungary in 1993. In addition to DRG based reimbursement, an degressive upper 
ceiling (financial cap) was introduced for hospital reimbursement. The aim of our 
study was to investigate the financial effects of degressive financing method on 
the Hungarian DRG-based hospital financing. Methods: The data in our analysis 
were derived from the nationwide administrative dataset of the National Health 
Insurance Fund Administration (OEP), the only health care financing agency. We 
examined the period between 2011 and 2013. In 2011 and 2012 hospital activity 
over financial cap was reimbursed up to 110% by 30% of DRG base rate, while in 
2013 hospital activity over financial cap was reimbursed up to 104% by 25% of 
DRG base rate. Results: In 2011 hospital activity exceeded the financial cap by 
4.6% with a monthly variation of 1.5% - 6.6%. In 2012 hospital activity exceeded 
the financial cap by 4.2% with a monthly variation of 1.1% - 6.5%. In 2013 hos-
pital activity exceeded the financial cap by 1.9% with a monthly variation of 
1.1% - 2.6%. Between 2011 and 2013 the DRG base rate remained the same (150000 
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adoPTion of oral diSeaSe modifying TreaTmenTS To manage PaTienTS 
wiTH relaPSing remiTTing mulTiPle ScleroSiS from 2011-2013 in THe 
uniTed STaTeS
Narayanan S.1, O’Meara P.2, White J.3, Chan J.3, Gabriele S.3, Hautamaki E.1
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objeCtives: New oral Disease Modifying Treatments (DMTs) for Relapsing 
Remitting Multiple Sclerosis (RRMS) were recently introduced in the US. The 
objective of this study was to assess trends in adoption of oral DMTs among 
RRMS patients in the US. Methods: A multi-center retrospective chart-review 
study of RRMS patients was conducted in the US in 4Q2011, 4Q2012, 2Q2013, and 
4Q2013 to collect de-identified data on diagnosis, clinical status, and treatment 
patterns. Neurologists were screened for duration of practice (≥ 3yrs) and patient 
volume (≥ 15 MS patients/mo) and recruited from a large panel to be geographi-
cally representative. Medical charts of next 10 consecutive MS patients were 
abstracted by each neurologist. RRMS patients taking oral, injectable, or infusible 
DMTs were analyzed. Results: 2362 eligible RRMS patient charts were evaluated 
(4Q2011:23%, 4Q2012:25%, 2Q2013:25% & 4Q2013:26%). Use of oral DMTs increased 
four-fold (4Q2011:7%, 4Q2012:9%, 2Q2013:21% & 4Q2013:31%); use of injectable 
DMTs decreased (4Q2011:82%, 4Q2012:78%, 2Q2013:71% & 4Q2013:60%), as did 
use of infusible DMTs (4Q2011:10%, 4Q2012:12%, 2Q2013:7% & 4Q2013:8%). Across 
timeframes, 61%, 27% & 12% of patients were on 1st-line, 2nd-line, and 3rd-line or 
subsequent treatment, respectively. Among 3rd-line or subsequent patients, oral 
DMT use increased from 23% to 59%; use of injectable and infusible DMTs decreased 
from 34% to 16% and 37% to 25%, respectively. Among 2nd-line patients, oral DMT 
use increased from 10% to 46%; use of injectable and infusible DMTs decreased 
from 66% to 37% and 21% to 15%, respectively. Among 1st-line patients, oral DMT 
use increased from 3% to 16%; use of injectable DMTs decreased from 96% to 83% 
and infusible DMT use remained at 1-2%. ConClusions: Oral DMT use increased 
between 4Q2011-4Q2013, predominantly in 2nd or subsequent lines. The impact of 
this observed pattern of reserving new treatment options for later lines warrants 
scrutiny to optimize patient management and alleviate disease burden.
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HealTH care uSe & Policy STudieS – consumer role in Health care
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awareneSS and inTereST in THe uniTed STaTeS HealTH inSurance 
markeTPlace
Bias T.K., Fitzgerald P.M., Agarwal P, Vasile E.
West Virginia University, Morgantown, WV, USA
objeCtives: To examine the level of awareness and interest in the newly setup 
Health Insurance Marketplace under Affordable Care Act in West Virginia state of 
the United States of America. Methods: Primary survey data were collected in 
July/August 2013 from a stratified sampling of West Virginians. A mail survey was 
completed by respondents in a cross-sectional study. Key variables included gen-
eral awareness of the Health Insurance Marketplace and the availability of subsi-
dies, the individual mandate, interest in using the Marketplace, and perceptions 
of respondents’ ability to qualify for financial assistance. Results: Six thousand 
surveys were mailed with a nine-page questionnaire. A total of 1,198 completed 
surveys were returned. Two months prior to launch, awareness of the Health 
Insurance Marketplace was low in WV; yet interest in the Marketplace was higher 
among those most likely to benefit—the insured and residents likely to qualify 
for financial subsidies. West Virginians reported being familiar with the individual 
mandate. ConClusions: Efforts should be increased at the federal, state, and local 
levels among government and non-government organizations to heighten aware-
ness of the Health Insurance Marketplace in WV and, particularly, the availability of 
subsidies. Many, once made aware, expressed interest in learning more.
PHP2
aTTiTudeS of PaTienTS Toward generic SubSTiTuTion and  
imPlicaTion for PracTice in Slovakia: firST reSulTS from  
adoPTing THe law in 2012
Babela R., Sajdikova K.
St. Elizabeth University, BRATISLAVA, Slovak Republic
objeCtives: Slovakia has from December 2011 new law that defines list of mol-
ecules for mandatory generic substitution. It was one of the cost-containment 
measures applied in the same time at the field of drug policy. We provided research 
on statistically selected sample of patients in Slovakia to detect current attitude, 
knowledge and believes toward generic substitution (GS). Methods: We created 
special questionnaire for patients and distributed it in selected regions in Slovakia. 
From 600 questionaires, we evaluated 432. Questionares were distributed among 
patients visiting pharmacies in 2013/2014 and all patients were older than 20 
years. Results: There were 57% of women in our sample and only 11% from all 
patients had lower than college education. 71% of all patients were using prescrip-
tion drugs regularly and 58% of all patients were familiar with term GS. Suprisingly, 
only 16% from all patients selected co-payment as the key factor influencing their 
decision toward GS. Recommendation of GS in pharmacy or by doctor was selected 
as key factor that influenced patients in choosing GS or generic molecule (40%). 
Second most influential factor was own experience with generic (27%). Only 8% 
of patients believed that GS can decrease overall consumption of drugs. We also 
found out that 36% of patients consider GS as “risky” because of extended number 
of generics available from various unknown companies. There was also a strong 
statistical relationship between gender and positives as well as negatives of GS 
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region) in each country. Overall rates of OT/PT visits were reported. Patients who 
reported an OT/PT visit in the past six months were compared with those who did 
not with respect to demographics, health history, and comorbidity variables. Logistic 
regression models were then conducted to predict OT/PT visits from these varia-
bles. Results: Rates of OT/PT visits did not change from 2010 to 2013 but significant 
differences among countries was observed (p< .05). In 2013, France (0.54%) and the 
US (4.51%) had the most infrequent visits while Spain (11.13%) and Germany (11.92%) 
had the most frequent. Being in Germany (OR= 3.46), being in Spain (OR= 3.24), and 
having an above the median income (OR= 1.14) were the strongest demographic 
predictors of an OT/PT visit (all p< .05). Although most comorbidities were associated 
with an increased probability of an OT/PT visit, pain (OR= 2.30), arthritis conditions 
(OR= 1.73), and psychiatric conditions (OR= 1.73) were most strongly associated (all 
p< .05). ConClusions: PT and OT utilization varies significantly across countries, 
being highest in Germany and Spain where over 10% of adults reported a visit in the 
past six months. Pain-related (pain, arthritis) and psychiatric comorbidities were 
among the strongest predictors of PT/OT use.
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a gender medicine PoST-Hoc analySiS: background and meTHodS of 
THe meTagem ProjecT
Simoni L.1, Colombo D.2, Bellia G.2, Vassellatti D.2, Zagni E.2, Rizzoli S.1, Sgarbi S.1
1Medidata srl, Modena, Italy, 2Novartis Farma Italy, Saronno (VA), Italy
objeCtives: Gender is a social construct, which is defined by the way people 
perceive themselves and how they expect others to behave. Gender medicine 
is the field of medicine that studies the biological and physiological differ-
ences between the human sexes and how that affects differences in disease. 
The progress of research has confirmed that men and women differ not only 
sexually but also in relationship to factors such as liver enzymes, sex hor-
mones and to variables determined by the environment, education, culture 
and psychology of the individual [Soldin and Mattison, 2009; Regitz-Zagrosek 
and Seeland 2012]. The Italian Drug Agency has recognized the importance of 
gender-specific analysis when evaluating new drug efficacy. The gender-medi-
cine METAGEM project aims to describe gender differences in clinical outcomes, 
therapeutic approach and safety parameters in real world data. Methods: 
Areas of interest were defined regarding Dermatology, Central nervous system, 
Infectivology, Rheumatology, and Transplantation; data were considered which 
were collected in ten observational studies conducted between 2002 and 2013 
in Italy in routine clinical practice. A post-hoc subgroup analysis is performed 
by study, during which males are compared with females by statistical tests. 
A merge of different study data will be performed in order to evaluate safety. 
As post-hoc analysis all p-values are exploratory. Results: The number of 
enrolled patients range between 238 to 1746 considering Rheumatology 
and Dermatology areas respectively, for a total of 3743 male and 3018 female 
patients. ConClusions: The papers and congress communications which will 
arise from METAGEM project will make the scientific community more aware of 
the importance of a gender-dedicated approach in the care of patients.
HealTH care uSe & Policy STudieS – drug/device/diagnostic use & Policy
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HealTH-economicS in czecH rePublic: can formal HealTH-economic 
meTHodology imProve THe QualiTy of SubmiTTed analySiS?
Hambalek J., Spurna M., Vocelka M., Ballokova A.
State Institute for Drug Control, Prague, Czech Republic
objeCtives: Health economic analysis (HEA) has been required since 2008 as a 
part of drug reimbursement applications submitted to the State Institute for Drug 
Control (SUKL). In 2013, SUKL introduced a formal health economic guideline, mostly 
based on the Czech Pharmacoenomic Society´s guideline published in 2011. The 
aim of this study was to assess the impact of guideline implementation on the 
quality of submitted HEAs. Methods: We reviewed all (18) applications for new 
innovative drugs with prescription limited to specialized centers, in which the 
final decision was issued and came into force between 1/2013-6/2014. The HEAs 
were described in terms of type of analysis and further confronted with a ‘HEA 
checklist‘ to identify common deficiencies in submitted HEAs. All check-lists were 
peer-reviewed to ensure objectivity. Our results were compared with previously 
published research (assessing HEAs submitted in 2008-2009 before the guideline 
release). Results: All investigated dossiers contained HEA. Nine of them (50%) 
were cost-effectiveness analysis (outcome expressed mostly in LYGs) and nine (50%) 
were cost-utility analyses (outcome in QALYs). In general, the quality of HEAs was 
higher compared to the previous research, with ‘evidence completeness’ and ‘uncer-
tainty’ being the most commonly marked as ‘unsatisfactory’ in the HEA checklist 
(less than 50%). Our results showed that 1/3 HEAs fell into the ‘best’ category (80-
100% ‘satisfactory’ questions), while none of HEAs fell into this category in previous 
research. ConClusions: The present analysis showed a trend in higher quality of 
submitted analyses (1/2013-6/2014) compared with years 2008-2009.
PHP12
Price comPariSon in THe euroPean PHarmaceuTical markeT
Ressl S., Walter E.
Institute for Pharmaeconomic Research, Vienna, Austria
objeCtives: Due to rising health care costs, stricter governmental cost contain-
ment measures like international price comparison and external reference pricing, 
the European pharmaceutical markets will lead to future challenges in pricing. 
Despite of these prices of pharmaceuticals vary across European countries. Thus, 
the aim of the analysis was to draw a comprehensive picture of the pharmaceuti-
cal price levels and consumption (expenditure per capita) of pharmaceuticals in 
Europe. Methods: The study analyzed drug prices of the outpatient setting (Rx 
and OTC) of all countries of the European Union except Denmark plus Switzerland. 
Hungarian Forint / DRG costweight). ConClusions: Introduction of degressive 
financing method – in addition to DRG reimbursement – managed to control the 
activity of hospitals. The soft regulation in 2011 and 2012 resulted in a 4.2-4.6% 
excess activity of hospitals, while the more rigorous regulation in 2013 managed to 
decrease the excess hospital activity to 1.9%. Degressive regulation can serve as a 
cost containment tool for health policy decision makers.
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nub STaTuS - a 2014 SiTuaTion analySiS for drugS: oncology aS 
leading THeraPeuTic area
Friedmann B.1, Keck E.2, Schalk E.3, Schmitz D.2
1Quintiles Commercial, Mannheim, Germany, 2Healthcare Manufaktur, Cologne, Germany, 
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objeCtives: In the German hospital landscape NuB’s (Neue Untersuchungs- und 
Behandlungsmethoden) are essentially the precursor for cost-intensive drugs to 
be reimbursed within the G-DRG system. Hospitals can only start SHI negotiations 
for reimbursement once drugs have been given a NuB 1 status. The objective of 
this research was to provide an overview on the proportion of drugs (vs. methods, 
medicinal products) and their respective indications, which submitted NuB applica-
tions for 2014. Methods: The German DRG database issued by the InEK (Institute 
for the Hospital Remuneration System) was used to analyse NuB subgroups sorted 
according to key therapeutic indications. In parallel, the number of NuB 1 status 
products that went through the AMNOG process was analysed. Results: Out of 
618 NuB submissions, only 133 (22%) were classified as drugs. In total, 114 (18%) 
of all NuB applications received a NuB 1 status, out of these 43 (38%) were drugs. 
The leading therapeutic area of the NuB 1 status drugs was oncology with 28 drugs 
(65%), followed by 5 ophthalmic products (12%). NuB 2 status was given to 465 (75%) 
procedures out of which 82 (18%) were drugs. The analysis reveals that, the suc-
cess rate to receive the essential NuB 1 status is relatively low. Chances to receive 
a successfull NuB 1 status approval is one in three for drugs, however only one in 
six for other procedures. Out of the 43 drugs that were given NuB 1 status, already 
24 (55%) passed through the AMNOG process and were given equal proportions 
from important additional benefit to no additional benefit. ConClusions: Drug 
applications are more likely than procedures to be given NuB 1 status and thereby 
initiate reimbursement negotiations with the SHI. The application quality and sup-
port by the scientific societies and treatment centres is essential to make a NuB 
application successful.
HealTH care uSe & Policy STudieS – diSeaSe managemenT
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mulTicriTeria deciSion analySiS and coST analySiS in HealTH care 
deciSion making: a liTeraTure review
Ivlev I., Landova M.
Czech Technical University in Prague, Kladno, Czech Republic
objeCtives: The purpose this literature review is to investigate the application of 
multicriteria decision analysis and cost analysis methods within health care deci-
sion-making. Methods: A search of the literature was conducted using scintific 
databases. A combination of the following key words and phrases were inputted 
into these databases: Analytic Hierarchy Process (AHP), Analytic Network Process 
(ANP), ELimination and Choice Expressing REality (ELECTRE), Goal programming, Grey 
relation analysis, Markov process, Technique for Order of Preference by Similarity 
to Ideal Solution (TOPSIS), CBA, CEA, and related words. The located articles were 
divided into the following twelve health care topics: evaluation of health informa-
tion services; evaluation of the product development process; project and technology 
selection; pharmaceutics; health care management; therapy/treatment; management 
of medical waste; human resource planning in health care; organ transplantation; 
evaluation of health care policy; diagnostics; and shared decision-making with the 
patient. Results: Ninety research articles were retrieved and determined relevant. 
The pertinent articles were published between 1981 and 2013. It was found that the 
AHP is the most commonly used method in health care decision making (65 articles). 
AHP is mainly exploited in project and technology selection (22). The ANP method 
is utilized in the evaluation of health information services, project and technology 
selection, pharmaceutics and therapy/treatment. For the evaluation of health care 
policy AHP (11), CBA (1), CEA (1) and Grey relation analysis (1) were used. The TOPSIS, 
VIKOR, Markov process methods were utilized once in human resource planning 
in health care, health care management and therapy/treatment respectively. The 
CBA (4) and CEA (2) methods were especially useful for solving therapy/treatment 
tasks. ConClusions: Multicriteria decision analysis and cost analysis offers a scien-
tifically sound evaluation framework for health care management, where stakeholder 
interests are of crucial concern and complex criteria that cannot easily be reduced to 
simple monetary expressions, can be assessed in resource limited settings.
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TrendS in PHySical and occuPaTional THeraPy uTilziaTion in THe uS 
and weSTern euroPe
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objeCtives: Allied health care (AHC) disciplines, such as physical (PT) and occupa-
tional therapy (OT), are primarily performed by non-medical health care profession-
als. Although the budget impact of AHC is generally low, reimbursements are often 
scrutinized for their financial impact and benefit/risk ratios. To better inform the 
health care decision making regarding AHC, the aim of this study was to examine 
trends and utilization of PT and OT. Methods: Data from the 2013 US (N= 75,000) 
and 2013 5EU (France, Germany, Italy, Spain, and UK; N= 62,000) National Health and 
Wellness Survey (NHWS). The NHWS is a patient-reported survey administered to 
a demographically representative sample of adults (with respect to age, sex, and 
